Intermittent fasting may help Type 1 diabetics control their blood sugar levels
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Oct-2026 06:16 ET (25-Oct-2026 10:16 GMT/UTC)
A correspondence published in The Lancet calls for national dialogues to shape green transition policies and counter fossil-fuel industry misinformation
Many cases of melanoma are treated with PD-1 blockade immunotherapy – a treatment that unleashes the body’s own immune system against cancer – which has demonstrated transformative results.
However, most melanoma patients treated with this immunotherapy eventually relapse. Understanding why has been one of the most pressing questions in cancer medicine.
UC Irvine researchers built a mathematical model of tumor immune activity to pinpoint a key cause of relapse: the rate at which PD-1 blockade immunotherapy activates regulatory T cells that infiltrate the tumor and suppress the tumor-killing response of the immune system. The team confirmed this math-driven prediction experimentally.
The findings point toward a promising new strategy: pairing PD-1 blockade immunotherapy with more targeted treatments that prevent immunosuppressive regulatory T cells from reaching the tumor. The model also provides a framework for testing other treatment combinations, offering a fast, cost-effective path to better therapies.
People who take part in screening for colorectal cancer may have as much as 43 per cent lower risk of dying from the disease, according to new estimates published in JAMA Network Open by researchers at Karolinska Institutet and Umeå University in Sweden. These findings are based on up to 14 years of follow-up data from the Stockholm–Gotland screening programme.
Prostate tumors can rewire amino acid metabolism to override the normal brakes on cholesterol production, a process that may fuel hormone therapy resistance, according to a study by Weill Cornell Medicine investigators.